ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.599,57
-0,46%
S&P 500
5.222,68
0,16%
US Dollar vs BRL
5,1376
-0,37%
Bitcoin
60.940,45
0,26%
Brent Oil
82,585
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Aldeyra Therapeutics Inc (ALDX)

  7. Aldeyra Therapeutics Inc (ALDX) Notícias

ALDX

Aldeyra Therapeutics (ALDX)

Aldeyra Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALDX
DataHoraFonteTítuloCódigoCompanhia
08/05/202408:00Business WireAldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
25/04/202408:00Business WireAldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development DayNASDAQ:ALDXAldeyra Therapeutics Inc
18/04/202408:00Business WireAldeyra Therapeutics to Host Research & Development Day on April 25, 2024NASDAQ:ALDXAldeyra Therapeutics Inc
28/03/202408:00Business WireAldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202418:54Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202418:48Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202418:40Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202418:06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALDXAldeyra Therapeutics Inc
06/02/202409:00Business WireAldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
29/01/202419:25Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALDXAldeyra Therapeutics Inc
04/01/202409:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
04/01/202409:00Business WireAldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory DiseasesNASDAQ:ALDXAldeyra Therapeutics Inc
19/12/202309:00Business WireAldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic DermatitisNASDAQ:ALDXAldeyra Therapeutics Inc
18/12/202318:01Business WireAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic DermatitisNASDAQ:ALDXAldeyra Therapeutics Inc
27/11/202318:07Business WireAldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
03/11/202317:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALDXAldeyra Therapeutics Inc
01/11/202308:05Business WireAldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize ReproxalapNASDAQ:ALDXAldeyra Therapeutics Inc
27/09/202306:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)NASDAQ:ALDXAldeyra Therapeutics Inc
11/09/202318:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
11/08/202306:45PR Newswire (US)ALDX SHAREHOLDER ALERT: Jakubowitz Law Reminds Aldeyra Shareholders of a Lead Plaintiff Deadline of September 29, 2023NASDAQ:ALDXAldeyra Therapeutics Inc
06/07/202308:00Business WireAldeyra Therapeutics to Participate in SVB Securities Therapeutics ForumNASDAQ:ALDXAldeyra Therapeutics Inc
29/06/202317:24Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALDXAldeyra Therapeutics Inc
29/06/202308:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALDXAldeyra Therapeutics Inc
29/06/202308:00Business WireAldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis PigmentosaNASDAQ:ALDXAldeyra Therapeutics Inc
28/06/202317:01Business WireAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis PigmentosaNASDAQ:ALDXAldeyra Therapeutics Inc
27/06/202308:00Business WireAldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic CoughNASDAQ:ALDXAldeyra Therapeutics Inc
26/06/202317:01Business WireAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic CoughNASDAQ:ALDXAldeyra Therapeutics Inc
23/06/202308:00Business WireAldeyra Therapeutics to Join the Russell 2000® and Russell 3000® IndexesNASDAQ:ALDXAldeyra Therapeutics Inc
21/06/202310:34Business WireAldeyra Therapeutics Provides Regulatory Update on ADX-2191NASDAQ:ALDXAldeyra Therapeutics Inc
15/06/202308:00Business WireAldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE‑2 Trial of Reproxalap in Allergic ConjunctivitisNASDAQ:ALDXAldeyra Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALDX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
YDUQ3
ESTACIO PART ON
BOV
MEAL3
IMC S/A ON
BOV
EMAE4
EMAE PN
BOV
OIBR3
OI ON
BOV
VVEO3
CM Hospitalar ON
BOV
AERI3
Aeris Industria E Comerc... ON
BOV
UNIP6
UNIPAR PNB
BOV
BHIA3
Grupo Casas Bahia ON
BOV
AMBP3
Ambipar Participacoes e ... ON
BOV
PDGR3
PDG REALT ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
COGN3
COGNA ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados